Clinical trial
Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
NCT00265148 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00265148 |
|---|---|
| Title | Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease |
| Official title | Effects of Avandia on Cognition and Cerebral Glucose Utilisation in Subjects With Mild to Moderate Alzheimer's Disease (AD). |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug, Other |
| Interventions | Rosiglitazone, Placebo |
| Enrollment | 80 |
| Start date | May 18, 2004 |
| Primary completion | Jul 10, 2008 |
| Completion | Jul 10, 2008 |
| First posted | Dec 14, 2005 |
| Last update posted | Nov 18, 2020 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: